Medical device and MedTech insights, news, tips and more

Mazor Robotics Set to Receive $20M Investment from Medtronic

July 12, 2016

Mazor Robotics

Mazor RoboticsMedtronic PLC is preparing to invest another $20 million in Israeli med-tech company Mazor Robotics, which is expected on Tuesday to announce a new robotically assisted spine-surgery system called Mazor X.

Analysts say physician interest in robotically assisted surgical tools is steadily growing, and Medtronic seems to be positioning itself to capitalize on the trend — and potentially accelerate it — if it takes off.

More than 16,000 successful spinal surgeries have been done worldwide with Mazor’s existing flagship guidance system, the Renaissance, and its predecessor. Last May, Mazor revealed that it had signed commercial agreements with Medtronic for up to $52 million in total potential investments from the Minnesota-run device company and exclusive distribution rights for new Mazor spine products.

At an investors presentation Tuesday in New York, Mazor is expected to announce plans to launch sales of its new robotic surgical-guidance system, Mazor X, which has already been cleared for U.S. sales by the U.S. Food and Drug Administration. The $850,000 system will go on sale this fall.

A Mazor news release says the unveiling of the Mazor X system will trigger Medtronic’s second-stage investment of up to $20 million in Mazor, pending satisfaction of other conditions in the agreement that aren’t specified.

In the first stage investment, announced last May, Medtronic paid $11.9 million to acquire 4 percent of Mazor’s shares. The second and third stages of Medtronic’s investments can be capped at $20 million, for a total investment of $51.9 million. The third stage is contingent on, among other things, the start of a global distribution agreement between Medtronic and Mazor.

Read Full Article – Source: Medtronic invests another $20 million in Mazor Robotics

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.